AzaSite

Leerink Swann analyst Joseph P. Schwartz reiterated his Outperform rating for shares of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) and raised the price target from $8 to $10. Swann discussed the implications of Inspire Pharmaceuticals' AzaSite product having entered into Phase II trials to treat...